Creating a new vector to track CAR T cell therapies in patients
Official title: The development of a GMP eDHFR vector to monitor investigational CAR T cell therapies
Funded at Vellum Biosciences LLC · NIH-11007670 · Data updated 2026-11-12
This study is testing a new way to track how well CAR T cell therapies work in cancer patients by using special imaging techniques, so doctors can see how these treatments are doing in the body over time.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vellum Biosciences LLC NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | August 7, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $300,000 |
| NIH project number | 1R41AI186797-01 |
| Project ID | NIH-11007670 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients undergoing CAR T cell therapy for cancer treatment.
✕Less likely to help
Patients who are not receiving CAR T cell therapies or those with conditions not targeted by this treatment may not benefit from this research.
What this research studies
This research focuses on developing a new viral vector that can help monitor the distribution and behavior of CAR T cell therapies in patients. By using advanced imaging techniques, specifically positron emission tomography (PET), the study aims to provide precise measurements of how these therapies perform over time in the body. The technology involves a synthetic antibiotic that can be used to visualize the activity of CAR T cells, which are engineered to target and destroy cancer cells. This approach is designed to enhance the understanding of CAR T cell therapies and improve their effectiveness in treating various cancers.
Why it matters
Potential benefit: If successful, this research could lead to better monitoring of CAR T cell therapies, ultimately improving treatment outcomes for cancer patients.
How similar studies have gone: Previous research has shown promise in using imaging technologies to monitor CAR T cell therapies, indicating that this approach has potential for success.
Where this research is happening
-
Vellum Biosciences LLC
Philadelphia, United States Active
Researchers
- Principal investigator: Miller, Derek — Vellum Biosciences LLC
- Study coordinator: Miller, Derek
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.